Biomarin Pharmaceutical (BMRN) Other Gross PP&E Adjustments (2016 - 2025)
Historic Other Gross PP&E Adjustments for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $2.0 billion.
- Biomarin Pharmaceutical's Other Gross PP&E Adjustments rose 382.46% to $2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year increase of 382.46%. This contributed to the annual value of $1.9 billion for FY2024, which is 118.34% up from last year.
- Latest data reveals that Biomarin Pharmaceutical reported Other Gross PP&E Adjustments of $2.0 billion as of Q3 2025, which was up 382.46% from $2.0 billion recorded in Q2 2025.
- Biomarin Pharmaceutical's Other Gross PP&E Adjustments' 5-year high stood at $2.0 billion during Q3 2025, with a 5-year trough of $1.7 billion in Q4 2021.
- For the 5-year period, Biomarin Pharmaceutical's Other Gross PP&E Adjustments averaged around $1.8 billion, with its median value being $1.9 billion (2024).
- Per our database at Business Quant, Biomarin Pharmaceutical's Other Gross PP&E Adjustments soared by 972.69% in 2021 and then plummeted by 39.18% in 2025.
- Over the past 5 years, Biomarin Pharmaceutical's Other Gross PP&E Adjustments (Quarter) stood at $1.7 billion in 2021, then increased by 7.45% to $1.8 billion in 2022, then increased by 2.83% to $1.8 billion in 2023, then rose by 1.18% to $1.9 billion in 2024, then grew by 6.67% to $2.0 billion in 2025.
- Its Other Gross PP&E Adjustments was $2.0 billion in Q3 2025, compared to $2.0 billion in Q2 2025 and $1.9 billion in Q1 2025.